Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

FUJIFILM submits final PMA module for Aspire Cristalle digital breast tomosynthesis option

FUJIFILM Medical Systems U.S.A., a leading provider of diagnostic imaging products and medical informatics solutions, has submitted to the U.S. Food and Drug Administration (FDA) the final module of its premarket approval (PMA) application for digital breast tomosynthesis* (DBT), as an optional software upgrade for the ASPIRE Cristalle digital mammography system.

The optional DBT upgrade for the ASPIRE Cristalle system, known as AMULET Innovality outside of the United States, has been available since May 2013 in Europe, Asia and Latin America.

“Today marks another milestone in Fujifilm’s mission to bring innovative digital breast tomosynthesis technology to physicians and women across America,” said Rob Fabrizio, Director of Strategic Marketing, Digital Radiography and Women’s Health, FUJIFILM Medical Systems U.S.A., Inc.

ASPIRE Cristalle is available in the United States today as a Full Field Digital Mammography System. ASPIRE Cristalle features Fujifilm's innovative hexagonal close pattern (HCP) detector pixel design, engineered for higher acquisition efficiency, to enhance detail for improved low dose performance compared to conventional square pixel design. The result is sharper images with gentler dose to the patient.

Additionally, ASPIRE Cristalle incorporates a patient calming design and Fujifilm’s patented Comfort Paddle which is designed to make the most physically unpleasant part of mammograms, more comfortable.

The paddle’s unique soft edges, flexible composition and 4-way pivot contours to the individual shape of the breast to more comfortably apply just the right compression for optimal tissue separation.

According to the National Cancer Institute at the National Institutes of Health (NIH), 1 in 8 women will be diagnosed with breast cancer in their lifetime.

 The stage at which breast cancer is detected influences a woman’s chance of survival. Fujifilm is dedicated to promoting the early detection of breast cancer through advances in digital mammography as well as supplementary screening or diagnostic testing.

Fujifilm continues to conduct research and collaborate with specialists in the field to develop revolutionary and reliable imaging technologies.